python3 -c " from docx import Document doc = Document('/tmp/workspace/attachments/30cefc6b-75fb-480c-bab6-93a13d981d7c/METHODOLOGY (1).docx') for p in doc.paragraphs: style = p.style.name if p.style else 'None' if p.text.strip(): print(f'[{style}] {p.text}') "

mkdir -p /tmp/workspace/md-thesis-methodology && python3 << 'PYEOF' from docx import Document from docx.shared import Pt, Inches, RGBColor from docx.enum.text import WD_ALIGN_PARAGRAPH from docx.oxml.ns import qn from docx.oxml import OxmlElement doc = Document() # ── Styles ────────────────────────────────────────────────────────────────── normal_style = doc.styles['Normal'] normal_style.font.name = 'Times New Roman' normal_style.font.size = Pt(12) from docx.shared import Pt def add_heading(doc, text, level=1): h = doc.add_heading(text, level=level) h.alignment = WD_ALIGN_PARAGRAPH.LEFT run = h.runs[0] if h.runs else h.add_run(text) run.font.name = 'Times New Roman' run.bold = True if level == 1: run.font.size = Pt(14) elif level == 2: run.font.size = Pt(13) else: run.font.size = Pt(12) return h def add_para(doc, text, bold=False, italic=False, indent=False): p = doc.add_paragraph() p.alignment = WD_ALIGN_PARAGRAPH.JUSTIFY if indent: p.paragraph_format.left_indent = Inches(0.4) run = p.add_run(text) run.font.name = 'Times New Roman' run.font.size = Pt(12) run.bold = bold run.italic = italic return p def add_bullet(doc, text, indent_level=0): p = doc.add_paragraph(style='List Bullet') p.paragraph_format.left_indent = Inches(0.5 + indent_level * 0.25) run = p.add_run(text) run.font.name = 'Times New Roman' run.font.size = Pt(12) return p def add_numbered(doc, text, n): p = doc.add_paragraph() p.paragraph_format.left_indent = Inches(0.4) run = p.add_run(f'{n}. {text}') run.font.name = 'Times New Roman' run.font.size = Pt(12) return p # ════════════════════════════════════════════════════════════════════════════ # TITLE # ════════════════════════════════════════════════════════════════════════════ title = doc.add_paragraph() title.alignment = WD_ALIGN_PARAGRAPH.CENTER r = title.add_run('CHAPTER III: MATERIALS AND METHODS') r.font.name = 'Times New Roman' r.font.size = Pt(14) r.bold = True doc.add_paragraph() # ════════════════════════════════════════════════════════════════════════════ # SECTION 1 — STUDY DESIGN & SETTING # ════════════════════════════════════════════════════════════════════════════ add_heading(doc, '3.1 Study Design and Setting', level=1) add_para(doc, 'This was a cross-sectional, observational study conducted in the Department of Microbiology at a tertiary care teaching hospital in Northwestern India. The study period spanned [mention duration, e.g., January 2023 to December 2023]. Ethical clearance was obtained from the Institutional Ethics Committee (IEC Ref. No.: ________) prior to data collection. Written informed consent was obtained from all participants before enrolment.') # ════════════════════════════════════════════════════════════════════════════ # SECTION 2 — SAMPLE COLLECTION # ════════════════════════════════════════════════════════════════════════════ add_heading(doc, '3.2 Sample Collection', level=1) add_para(doc, 'Midstream clean-catch urine specimens were collected from patients presenting with clinical features of urinary tract infection (UTI), including dysuria, frequency, urgency, and suprapubic discomfort. Catheterised urine specimens were collected from patients with indwelling urinary catheters under strict aseptic precautions. All samples were transported to the microbiology laboratory within two hours of collection. Specimens that could not be processed immediately were stored at 4°C and processed within four hours of receipt. Samples showing signs of contamination (squamous epithelial cell count > 10 per low-power field on microscopy) were rejected and a repeat specimen was requested.') # ════════════════════════════════════════════════════════════════════════════ # SECTION 3 — CULTURE AND PRIMARY ISOLATION # ════════════════════════════════════════════════════════════════════════════ add_heading(doc, '3.3 Culture and Primary Isolation', level=1) add_para(doc, 'Each urine specimen was inoculated onto 5% sheep blood agar and MacConkey agar using a calibrated loop delivering 0.001 mL. Plates were incubated aerobically at 37°C for 18–24 hours. Significant bacteriuria was defined as the growth of ≥ 10⁵ colony-forming units per millilitre (CFU/mL) of urine. Specimens yielding growth of two or more distinct organisms were considered polymicrobial; however, if the clinical suspicion was strong, both isolates were identified and reported.') # ════════════════════════════════════════════════════════════════════════════ # SECTION 4 — IDENTIFICATION OF ISOLATES # ════════════════════════════════════════════════════════════════════════════ add_heading(doc, '3.4 Identification of Isolates', level=1) add_para(doc, 'Bacterial isolates were identified through a systematic approach incorporating colony morphology, Gram staining characteristics, motility testing, and a panel of conventional biochemical reactions. Where indicated, results were corroborated using commercially available identification systems.') # 4.1 Colony Morphology add_heading(doc, '3.4.1 Colony Morphology', level=2) add_para(doc, 'Colonies growing on blood agar and MacConkey agar were evaluated for size, shape, surface texture, margin, elevation, opacity, pigmentation, haemolytic pattern (on blood agar), and any distinctive odour. These macroscopic features provided initial presumptive identification of the isolate.') # 4.2 Gram Staining add_heading(doc, '3.4.2 Gram Staining', level=2) add_para(doc, 'Thin films were prepared on clean, grease-free glass slides from 18–24 hour cultures, air-dried, and heat-fixed by brief flaming. The standard four-step Gram staining procedure was performed as follows:') steps_gram = [ 'The dried smear was flooded with crystal violet (primary stain) and allowed to act for one minute, after which the excess stain was rinsed gently with distilled water.', 'Gram\'s iodine solution was then applied for one minute. Iodine acts as a mordant, forming a crystal violet-iodine complex within the cell.', 'Decolorisation was performed with acetone-alcohol until the solvent ran clear, followed immediately by washing with water to stop decolorisation.', 'Counter-staining was carried out with diluted carbol fuchsin (1:10 dilution) for 30 seconds. The slide was washed, blot-dried, and examined under oil-immersion (×100 objective).', ] for i, s in enumerate(steps_gram, 1): add_numbered(doc, s, i) add_para(doc, '') add_para(doc, 'Principle:', bold=True) add_para(doc, 'The Gram staining differential is based on differences in cell-wall architecture. Gram-positive organisms possess a thick, multilayered peptidoglycan cell wall (50–100 nm) with extensive cross-linkages that retains the crystal violet-iodine complex during decolorisation, resulting in a purple colour. Gram-negative organisms, by contrast, have a thinner peptidoglycan layer (2–7 nm) enclosed by an outer lipopolysaccharide membrane that is disrupted by the acetone-alcohol decoloriser, allowing the primary complex to leach out; these cells subsequently absorb the safranin counter-stain and appear pink.') add_para(doc, 'Interpretation of Results:', bold=True) add_bullet(doc, 'Gram-positive organisms: Deep violet to purple') add_bullet(doc, 'Gram-negative organisms: Pink to red') add_para(doc, 'Quality Control Strains:', bold=True) add_bullet(doc, 'Gram-positive control: Staphylococcus aureus ATCC 25923') add_bullet(doc, 'Gram-negative control: Escherichia coli ATCC 25922') # 4.3 Motility add_heading(doc, '3.4.3 Motility Test', level=2) add_para(doc, 'Bacterial motility was assessed using the hanging-drop preparation method. A fresh 6–8 hour broth culture was used. A small drop of the suspension was placed on a coverslip, which was then inverted over a concave well-slide and sealed with petroleum jelly at the margins. The preparation was examined under the ×40 objective. True motility was distinguished from Brownian motion by observing directional displacement of cells.') # ════════════════════════════════════════════════════════════════════════════ # SECTION 5 — BIOCHEMICAL IDENTIFICATION # ════════════════════════════════════════════════════════════════════════════ add_heading(doc, '3.5 Biochemical Tests for Identification', level=1) add_para(doc, 'Based on Gram staining results, isolates were subjected to the biochemical reactions described below. All reagents and media were prepared according to the formulations outlined in standard references (Mackie & McCartney; Collee et al.). Quality control was maintained using the ATCC reference strains specified for each test.') # ── GRAM-POSITIVE ────────────────────────────────────────────────────────── add_heading(doc, '3.5.1 Gram-Positive Cocci', level=2) # Catalase add_para(doc, '(a) Catalase Test', bold=True) add_para(doc, 'The catalase test was performed to detect the enzyme catalase, which decomposes hydrogen peroxide (H₂O₂) into water and oxygen gas. Three to five colonies from a pure culture on nutrient agar were transferred using a sterile glass rod to a clean glass slide containing one drop of freshly prepared 3% H₂O₂ solution. Immediate brisk effervescence (bubble formation) constituted a positive result.') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Positive control: Staphylococcus aureus ATCC 25923') add_bullet(doc, 'Negative control: Streptococcus pyogenes ATCC 19615') # Coagulase add_para(doc, '(b) Coagulase Test', bold=True) add_para(doc, 'The coagulase test differentiates Staphylococcus aureus (coagulase-positive) from coagulase-negative staphylococci (CoNS). Two forms of coagulase were tested:') add_para(doc, 'Slide Coagulase Test (Bound Coagulase):', italic=True) add_para(doc, 'A single isolated colony was emulsified in a small drop of physiological saline on a glass slide to form a smooth suspension. A drop of undiluted rabbit plasma was added and mixed. The slide was rocked gently for 5–10 seconds. Coarse, visible clumping within this period indicated a positive result. Strains giving a doubtful or negative slide test were confirmed by the tube coagulase test.', indent=True) add_para(doc, 'Tube Coagulase Test (Free Coagulase):', italic=True) add_para(doc, 'A 1:6 dilution of rabbit plasma in normal saline (0.85% NaCl) was prepared. One millilitre of the diluted plasma was dispensed into each of three labelled test tubes. The test isolate was inoculated into the first tube; known positive (S. aureus ATCC 25923) and negative (S. epidermidis ATCC 12228) control strains were inoculated into the remaining two tubes; a fourth tube containing uninoculated diluted plasma served as a spontaneous-clotting control. Tubes were incubated at 37°C in a water bath and examined at 1, 2, and 4 hours for clot formation by tilting through 90°. Tubes remaining negative at 4 hours were left at room temperature and re-read after overnight incubation.', indent=True) add_bullet(doc, 'Positive result: Any degree of clot formation in the test tube') add_bullet(doc, 'Negative result: Absence of clot formation') # CAMP add_para(doc, '(c) CAMP Test', bold=True) add_para(doc, 'The Christie-Atkins-Munch-Petersen (CAMP) test was used to presumptively identify Group B Streptococcus (Streptococcus agalactiae). S. agalactiae secretes a diffusible extracellular protein (CAMP factor) that acts synergistically with the beta-lysin produced by S. aureus to cause enhanced lysis of sheep erythrocytes. A beta-lysin-producing strain of S. aureus was streaked as a single straight line down the centre of a 5% sheep blood agar plate. Test organisms were streaked perpendicularly to this line, stopping approximately 2 mm from it. Plates were incubated overnight at 35–37°C in air or in 5–10% CO₂. Enhanced haemolysis in an arrowhead configuration at the junction of the two organisms constituted a positive result.') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Positive control: Streptococcus agalactiae ATCC 13813 (arrowhead haemolysis)') add_bullet(doc, 'Negative control: Streptococcus pyogenes ATCC 19615 (beta-haemolysis without arrowhead enhancement)') # Bile Solubility add_para(doc, '(d) Bile Solubility Test', bold=True) add_para(doc, 'This test differentiated Streptococcus pneumoniae (bile-soluble) from other alpha-haemolytic streptococci (bile-insoluble). Following 18–24 hours of incubation on 5% sheep blood agar, one to two drops of 10% sodium deoxycholate solution were placed directly on a well-isolated colony without mechanically disturbing it. The plate was incubated at 37°C for 30 minutes and then observed for lysis (disappearance) of the colony. Alternatively, a tube method using 2% sodium deoxycholate was employed. Dissolution of the colony represented a positive (bile-soluble) result.') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Positive control: Streptococcus pneumoniae ATCC 49613') add_bullet(doc, 'Negative control: Enterococcus faecalis ATCC 29219') # Optochin add_para(doc, '(e) Optochin Sensitivity Test', bold=True) add_para(doc, 'Optochin (ethylhydrocupreine hydrochloride) sensitivity is used to distinguish S. pneumoniae (susceptible) from other alpha-haemolytic streptococci (resistant). A standardised suspension of the test organism was streaked evenly onto a sheep blood agar plate. An optochin disc (6 mm) was placed on the inoculated surface, and the plate was incubated at 35°C in 5–10% CO₂ for 18–24 hours. Optochin disrupts the ATP synthase complex of pneumococci, resulting in growth inhibition. A zone of inhibition of 14 mm or greater around the disc was interpreted as susceptibility.') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Positive control: Streptococcus pneumoniae ATCC 6305') add_bullet(doc, 'Negative control: Streptococcus pyogenes ATCC 12384') # Bacitracin add_para(doc, '(f) Bacitracin Sensitivity Test', bold=True) add_para(doc, 'Bacitracin sensitivity (TaxoA disc, 0.04 units) was used for the presumptive identification of Group A Streptococcus (S. pyogenes), which is susceptible, and its differentiation from other beta-haemolytic streptococci, which are resistant. Two to three suspected colonies were streaked onto a blood agar plate, a bacitracin disc was placed on the primary inoculation zone, and the plate was incubated for 18–24 hours at 35–37°C. A zone of inhibition greater than 10 mm was considered a positive (susceptible) result.') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Positive control: Streptococcus pyogenes ATCC 19615 (susceptible)') add_bullet(doc, 'Negative controls: Streptococcus agalactiae ATCC 27956; Staphylococcus aureus ATCC 25923 (resistant)') # ── GRAM-NEGATIVE ────────────────────────────────────────────────────────── add_heading(doc, '3.5.2 Gram-Negative Bacilli', level=2) # Catalase (GN) add_para(doc, '(a) Catalase Test', bold=True) add_para(doc, 'The method described for Gram-positive cocci was applied. Escherichia coli ATCC 25922 (positive) and Streptococcus pyogenes (negative) served as controls.') # Oxidase add_para(doc, '(b) Oxidase Test', bold=True) add_para(doc, 'The oxidase test detects the presence of cytochrome c oxidase in the bacterial electron transport chain. An oxidase test disc (impregnated with 1% tetramethyl-p-phenylenediamine dihydrochloride) was placed on a clean filter paper on a glass slide. A portion of a selected colony was transferred onto the disc using a glass rod (metal implements were avoided to prevent false-positive reactions). Development of a dark purple colour within 10 seconds was recorded as a positive result.') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Positive control: Pseudomonas aeruginosa ATCC 27853') add_bullet(doc, 'Negative control: Escherichia coli ATCC 25922') # Sugar Fermentation add_para(doc, '(c) Carbohydrate Fermentation Tests', bold=True) add_para(doc, 'Organisms were inoculated into peptone water broth containing individual carbohydrates at 1% concentration and an inverted Durham tube to detect gas production. Andrade\'s indicator was incorporated into the medium. Tubes were incubated at 37°C for up to 18 hours. Acid production was detected as a colour change from pale yellow to pink-red; gas production was indicated by displacement of liquid in the Durham tube.') add_bullet(doc, 'Positive result: Pink-red colour change with or without gas in the Durham tube') add_bullet(doc, 'Negative result: Bacterial growth without any colour change') # Indole add_para(doc, '(d) Indole Test', bold=True) add_para(doc, 'The indole test assesses the ability of an organism to cleave tryptophan to indole, pyruvate, and ammonia via the enzyme tryptophanase. The test organism was inoculated into tryptone water broth (composition: peptone 20 g, sodium chloride 5 g, distilled water 1 L; pH 7.4; sterilised by autoclaving at 121°C) and incubated at 37°C for 18–24 hours. Following incubation, 0.5 mL of Kovac\'s reagent (isoamyl alcohol 150 mL, p-dimethylaminobenzaldehyde 10 g, concentrated hydrochloric acid 50 mL) was added along the wall of the tube. The reagent reacts with indole to produce a red-coloured quinoidal compound that concentrates in the alcohol layer.') add_bullet(doc, 'Positive result: Bright red ring in the upper alcohol layer') add_bullet(doc, 'Negative result: Yellow ring in the alcohol layer') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Positive control: Escherichia coli ATCC 25922') add_bullet(doc, 'Negative control: Klebsiella pneumoniae ATCC 76901') # MR add_para(doc, '(e) Methyl Red (MR) Test', bold=True) add_para(doc, 'The methyl red test detects mixed-acid fermentation, in which glucose is metabolised to produce stable, high-concentration acid end products (principally formic, acetic, and lactic acids) that lower the pH of the medium below 4.4. The organism was inoculated into glucose-phosphate peptone broth (peptone 5 g, di-potassium hydrogen phosphate 5 g, glucose 50 mL of 10% solution, distilled water 1 L; pH 7.6; dispensed in 5 mL volumes; sterilised at 121°C for 15 minutes) and incubated at 37°C for 48 hours (extended to 5 days if the initial result was equivocal). Five drops of methyl red indicator solution (methyl red 0.1 g, ethanol 300 mL, distilled water 200 mL) were added and the result was read immediately.') add_bullet(doc, 'Positive result: Persistent bright red colour (pH ≤ 4.4)') add_bullet(doc, 'Negative result: Yellow or orange colour (pH > 4.4)') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'MR-positive: Escherichia coli ATCC 25922') add_bullet(doc, 'MR-negative: Enterobacter aerogenes ATCC 13048') # VP add_para(doc, '(f) Voges-Proskauer (VP) Test', bold=True) add_para(doc, 'The VP test detects the production of acetoin (acetyl methyl carbinol) from glucose fermentation via the butylene glycol pathway. Under alkaline conditions in the presence of oxygen, acetoin is oxidised to diacetyl, which reacts with guanidine-containing compounds in peptone to produce a red colour. The test organism was inoculated into the same glucose-phosphate broth used for the MR test and incubated at 37°C for 48 hours. After incubation, 1 mL of 40% potassium hydroxide solution and 3 mL of 5% alpha-naphthol in absolute ethanol were added in that order. The tube was shaken vigorously to ensure aeration and observed for colour development over 30 minutes.') add_bullet(doc, 'Positive result: Development of a pink colour within 2–5 minutes, progressing to crimson red within 30 minutes') add_bullet(doc, 'Negative result: No colour change') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'VP-positive: Enterobacter aerogenes ATCC 13048') add_bullet(doc, 'VP-negative: Escherichia coli ATCC 25922') # Citrate add_para(doc, '(g) Citrate Utilisation Test', bold=True) add_para(doc, 'This test determines the ability of an organism to utilise sodium citrate as the sole carbon and energy source and ammonium dihydrogen phosphate as the sole nitrogen source. Bacteria capable of growing on Simmons\' citrate agar produce citrate permease, converting citrate to pyruvate, which then enters central metabolic pathways. Utilisation of ammonium salt releases ammonia, creating an alkaline environment that shifts the bromothymol blue indicator from green to blue. The test medium (sodium chloride 5 g, magnesium sulphate 0.2 g, ammonium dihydrogen phosphate 1 g, potassium dihydrogen phosphate 1 g, sodium citrate 5 g, agar 20 g, bromothymol blue 0.2% solution 40 mL, distilled water 1 L) was dispensed as slants. The surface of each slant was inoculated with a light inoculum using a straight wire and incubated at 37°C for up to 96 hours.') add_bullet(doc, 'Positive result: Blue colour with visible growth on the slant') add_bullet(doc, 'Negative result: No colour change; medium remains green with no growth') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Positive control: Enterobacter aerogenes ATCC 13048') add_bullet(doc, 'Negative control: Escherichia coli ATCC 25922') # TSI add_para(doc, '(h) Triple Sugar Iron (TSI) Agar Test', bold=True) add_para(doc, 'Triple sugar iron agar simultaneously assesses the fermentation of glucose, lactose, and sucrose, the production of hydrogen sulphide (H₂S), and gas generation. The test medium contained beef extract 3 g, yeast extract 3 g, peptone 20 g, glucose 1 g, lactose 10 g, sucrose 10 g, ferric citrate 0.3 g, sodium chloride 5 g, sodium thiosulphate 0.3 g, agar 12 g, phenol red indicator 12 mL, and distilled water 1 L. The constituents were dissolved by heating, the indicator was added, and the medium was distributed into tubes, sterilised at 121°C for 15 minutes, and allowed to solidify as slopes with 3 cm butts. The test organism was inoculated by surface-streaking the slope and stabbing into the butt with a straight wire. Tubes were incubated aerobically at 37°C for 18–24 hours and read without delay to avoid erroneous alkaline reversion results.') add_para(doc, 'Interpretation of Results (Slope / Butt):', bold=True) add_bullet(doc, 'K/K (Alkaline/Alkaline): Non-fermenter (e.g., Pseudomonas spp.)') add_bullet(doc, 'K/A (Alkaline/Acid): Only glucose fermented (e.g., Shigella spp.)') add_bullet(doc, 'A/A (Acid/Acid): Glucose + lactose/sucrose fermented (e.g., Escherichia coli)') add_bullet(doc, 'A/A + gas: Glucose + lactose fermented with gas production (e.g., Klebsiella spp.)') add_bullet(doc, 'K/A + H₂S: Only glucose fermented with H₂S production (e.g., Salmonella spp.)') add_bullet(doc, 'Black precipitate in butt: Ferrous sulphide, indicating H₂S production') add_para(doc, 'Quality Control Strains:', bold=True) add_bullet(doc, 'A/AG (acid slant, acid butt + gas): Escherichia coli ATCC 25922') add_bullet(doc, 'K/A + H₂S: Salmonella typhimurium ATCC 14028') add_bullet(doc, 'K/K: Pseudomonas aeruginosa ATCC 27853') add_bullet(doc, 'K/K + H₂S: Proteus mirabilis ATCC 12453') add_bullet(doc, 'K/A: Shigella flexneri ATCC 12022') # Urease add_para(doc, '(i) Urease Test', bold=True) add_para(doc, 'The urease test detects the enzyme urease, which hydrolyses urea to yield ammonia and carbon dioxide. The ammonia produced raises the pH of the medium, which is detected by the colour change of phenol red indicator from light orange to bright pink-purple. Christensen\'s urea agar (peptone 1 g, sodium chloride 5 g, dipotassium hydrogen phosphate 2 g, phenol red indicator 6 mL, agar 20 g, glucose 10% solution 10 mL, urea 20% solution 100 mL, distilled water 1 L; pH adjusted to 6.8–6.9) was prepared; the basal medium was autoclaved at 121°C for 30 minutes, cooled to 50°C, and glucose and sterile urea solutions were aseptically added before pouring deep slopes. The medium was inoculated heavily over the entire slope surface and incubated at 37°C; readings were taken at 4 hours and again after overnight incubation.') add_bullet(doc, 'Positive result: Bright pink-purple colour change throughout the medium') add_bullet(doc, 'Negative result: No colour change; medium retains its original orange-yellow hue') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Positive control: Proteus vulgaris ATCC 13315') add_bullet(doc, 'Negative control: Escherichia coli ATCC 25922') # Nitrate add_para(doc, '(j) Nitrate Reduction Test', bold=True) add_para(doc, 'The nitrate reduction test identifies organisms possessing nitrate reductase, the enzyme responsible for reducing nitrate to nitrite under anaerobic conditions. The test medium was prepared by dissolving peptone 5 g and potassium nitrate 0.2 g in 1 L of distilled water and dispensing 5 mL per tube; sterilisation was performed at 121°C for 15 minutes. Test organisms were inoculated and incubated for 96 hours at 37°C. The test reagent (freshly prepared by mixing equal volumes of Solution A: 8 g sulphanilic acid per litre of 5 mmol/L acetic acid; and Solution B: 5 g alpha-naphthylamine per litre of 5 mmol/L acetic acid) was then added (0.1 mL). Nitrite present in the medium reacts with sulphanilic acid to form a diazonium salt, which then couples with alpha-naphthylamine to produce a red azo dye.') add_bullet(doc, 'Positive result: Appearance of red colour within a few minutes of reagent addition') add_bullet(doc, 'Negative result: No colour development; zinc dust was added as a confirmatory step - remaining red indicated that no nitrate was present to be reduced') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Positive control: Proteus mirabilis ATCC 12453') add_bullet(doc, 'Negative control: Escherichia coli ATCC 19606') # Motility Test add_para(doc, '(k) Motility Test (Semi-Solid Agar)', bold=True) add_para(doc, 'The semi-solid agar motility test provides a definitive assessment of bacterial motility under incubation conditions. A straight inoculating needle was touched lightly to a colony from an 18–24 hour agar culture and stabbed once into the centre of a semi-solid motility agar deep to a depth of approximately one-third of the medium. Tubes were incubated at 37°C and examined at 24 and 48 hours. Motile organisms migrate outward from the stab line, producing diffuse turbidity that spreads through the medium, readily visible to the naked eye.') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Motile (positive): Escherichia coli ATCC 25922') add_bullet(doc, 'Non-motile (negative): Staphylococcus aureus ATCC 25923') # OF Test add_para(doc, '(l) Oxidative-Fermentative (O/F) Test - Hugh and Leifson Method', bold=True) add_para(doc, 'The Hugh and Leifson O/F test distinguishes oxidative metabolism from fermentative metabolism of glucose, and identifies organisms that are metabolically inert. The test medium contained peptone 2 g, sodium chloride 5 g, dipotassium hydrogen phosphate 0.3 g, agar 3 g, bromothymol blue 1% solution 3 mL, and glucose 1% sterile solution; distilled water 1 L; pH 7.1; autoclaved at 121°C for 15 minutes; carbohydrate added aseptically after cooling. Medium was dispensed to a depth of approximately 4 cm in tubes. Two tubes of dextrose medium were inoculated per organism by stabbing a needle four to five times to a depth of 1 cm from an 18–24 hour culture. One tube was sealed with sterile paraffin oil (anaerobic tube) and the other was left open (aerobic tube). Tubes were incubated at 37°C for up to 7 days and examined at regular intervals.') add_bullet(doc, 'Fermentative: Acid (yellow) in both open and sealed tubes') add_bullet(doc, 'Oxidative: Acid (yellow) in open tube only; sealed tube remains green or alkaline') add_bullet(doc, 'Inert/Alkalinogenic: Both tubes remain unchanged or become alkaline (blue)') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Fermentative: Escherichia coli ATCC 25922') add_bullet(doc, 'Oxidative: Pseudomonas aeruginosa ATCC 27853') # Amino Acid Decarboxylase add_para(doc, '(m) Amino Acid Decarboxylase Test', bold=True) add_para(doc, 'This test assesses the ability of an organism to enzymatically decarboxylate specific amino acids (lysine, ornithine, and arginine), releasing diamines that alkalinise the medium. The basal medium consisted of peptone 5 g, meat extract 5 g, glucose 0.5 g, pyridoxal 5 mg, bromocresol purple (1:500 solution) 5 mL, cresol red (1:500 solution) 2.5 mL, and distilled water 1 L; pH adjusted to 6.0 before the addition of indicators. The basal medium was divided into four portions: L-lysine hydrochloride 1% (tube 1), L-ornithine hydrochloride 1% (tube 2), L-arginine hydrochloride 1% (tube 3), and no amino acid (tube 4, control). pH was re-adjusted to 6.0; 1 mL volumes were dispensed into small tubes overlaid with 5 mm of sterile liquid paraffin and sterilised at 121°C for 15 minutes. Organisms were inoculated through the paraffin layer using a straight wire and incubated at 37°C for up to four days. The medium initially turned yellow due to glucose fermentation, followed by a violet/purple colour change upon decarboxylation of the amino acid; the control tube was expected to remain yellow.') add_para(doc, 'Quality Control:', bold=True) add_bullet(doc, 'Lysine-positive: Klebsiella pneumoniae ATCC 33495 (yellow → purple)') add_bullet(doc, 'Ornithine-positive: Enterobacter aerogenes ATCC 13048 (yellow → purple)') add_bullet(doc, 'Arginine-positive: Pseudomonas aeruginosa ATCC 27853 (yellow → purple)') add_bullet(doc, 'Lysine-negative: Citrobacter freundii ATCC 33118 (remains yellow)') add_bullet(doc, 'Ornithine-negative: Proteus vulgaris ATCC 6380 (remains yellow)') add_bullet(doc, 'Arginine-negative: Escherichia coli ATCC 25922 (remains yellow)') # ════════════════════════════════════════════════════════════════════════════ # SECTION 6 — ANTIMICROBIAL SUSCEPTIBILITY TESTING # ════════════════════════════════════════════════════════════════════════════ add_heading(doc, '3.6 Antimicrobial Susceptibility Testing', level=1) add_para(doc, 'Antimicrobial susceptibility testing was performed using the Kirby-Bauer disc diffusion method on Mueller-Hinton agar, in accordance with the guidelines of the Clinical and Laboratory Standards Institute (CLSI, latest edition at the time of the study). Mueller-Hinton agar was prepared according to the manufacturer\'s instructions and poured to a uniform depth of 4 mm in 90 mm Petri dishes. Plates were stored at 4°C when not in immediate use and allowed to equilibrate to room temperature before use.') add_para(doc, '3.6.1 Inoculum Preparation', bold=True) add_para(doc, 'Three to five well-isolated colonies of the same morphological type were selected from an overnight culture on blood agar or MacConkey agar and emulsified in 4–5 mL of sterile normal saline. The turbidity of the suspension was adjusted to match the 0.5 McFarland standard (equivalent to approximately 1–2 × 10⁸ CFU/mL) by visual comparison against an illuminated white background with contrasting black lines. Inocula were used within 15 minutes of preparation.') add_para(doc, '3.6.2 Inoculation of Plates', bold=True) add_para(doc, 'A sterile cotton swab was immersed in the standardised bacterial suspension and the excess inoculum was expressed by firmly pressing and rotating the swab against the inner wall of the tube. The dried surface of a Mueller-Hinton agar plate was inoculated by streaking the swab evenly across the entire agar surface in three directions, rotating the plate by approximately 60° between each pass to ensure uniform bacterial distribution. The inoculum was allowed to dry for 3–5 minutes at room temperature before disc application.') add_para(doc, '3.6.3 Antibiotic Disc Application and Incubation', bold=True) add_para(doc, 'Commercially available antibiotic discs of defined potency (HiMedia/Oxoid) were placed on the inoculated agar surface using sterile forceps or a disc dispenser. Each disc was gently pressed down with forceps to ensure full contact with the agar. Discs were positioned at least 24 mm apart (centre to centre) to prevent zone overlap, and no disc was placed closer than 15 mm from the plate edge. No more than six discs were placed per 90 mm plate. Plates were inverted and incubated aerobically at 37°C for 16–18 hours. For isolates with suspected inducible resistance (e.g., MRSA), incubation was extended to 24 hours.') add_para(doc, '3.6.4 Zone Measurement and Interpretation', bold=True) add_para(doc, 'Following incubation, the diameter of each zone of complete inhibition (including the 6 mm disc) was measured to the nearest millimetre using a calibrated ruler or zone reader on the underside of the plate against a black background with reflected light. Swarming Proteus spp. were read at the margin of obvious growth reduction. Zone diameters were interpreted as Susceptible (S), Intermediate (I), or Resistant (R) according to current CLSI breakpoint tables. Results were reported accordingly for each antimicrobial agent tested.') add_para(doc, '3.6.5 Quality Control', bold=True) add_para(doc, 'Quality control testing was performed on each day of testing using the following ATCC reference strains:') add_bullet(doc, 'Escherichia coli ATCC 25922') add_bullet(doc, 'Staphylococcus aureus ATCC 25923') add_bullet(doc, 'Pseudomonas aeruginosa ATCC 27853') add_bullet(doc, 'Klebsiella pneumoniae ATCC 700603 (for extended-spectrum beta-lactamase screening)') add_para(doc, 'Zone diameters obtained for control strains were compared with CLSI-specified acceptable ranges. Any deviation outside the acceptable range prompted investigation and repeat testing before patient results were reported.') add_para(doc, '3.6.6 Panel of Antibiotic Discs Tested', bold=True) add_para(doc, 'The antibiotics tested were selected based on CLSI recommendations for uropathogens and the antibiogram policy of the institution. The panel included, but was not limited to, the agents listed in the table below (Table 3.1). Disc potencies were as per CLSI M100 standard recommendations.') # Antibiotic table table = doc.add_table(rows=1, cols=3) table.style = 'Table Grid' hdr_cells = table.rows[0].cells for i, h in enumerate(['Antibiotic Class', 'Antibiotic Agent', 'Disc Potency']): hdr_cells[i].text = h for run in hdr_cells[i].paragraphs[0].runs: run.bold = True run.font.name = 'Times New Roman' run.font.size = Pt(11) antibiotics = [ ('Penicillins', 'Ampicillin', '10 µg'), ('Penicillin + BLI', 'Amoxicillin-Clavulanate', '20/10 µg'), ('Cephalosporins (1st gen)', 'Cephalexin / Cefazolin', '30 µg'), ('Cephalosporins (2nd gen)', 'Cefuroxime', '30 µg'), ('Cephalosporins (3rd gen)', 'Cefotaxime / Ceftriaxone', '30 µg'), ('Cephalosporins (3rd gen)', 'Ceftazidime', '30 µg'), ('Cephalosporins (4th gen)', 'Cefepime', '30 µg'), ('Carbapenems', 'Imipenem', '10 µg'), ('Carbapenems', 'Meropenem', '10 µg'), ('Carbapenems', 'Ertapenem', '10 µg'), ('Fluoroquinolones', 'Ciprofloxacin', '5 µg'), ('Fluoroquinolones', 'Norfloxacin', '10 µg'), ('Fluoroquinolones', 'Levofloxacin', '5 µg'), ('Aminoglycosides', 'Gentamicin', '10 µg'), ('Aminoglycosides', 'Amikacin', '30 µg'), ('Tetracyclines', 'Tetracycline / Doxycycline', '30 µg'), ('Folate pathway inhibitor', 'Cotrimoxazole (TMP-SMX)', '1.25/23.75 µg'), ('Nitrofurans', 'Nitrofurantoin', '300 µg'), ('Glycopeptides', 'Vancomycin', '30 µg'), ('Glycopeptides', 'Teicoplanin', '30 µg'), ('Lincosamides', 'Clindamycin', '2 µg'), ('Macrolides', 'Erythromycin', '15 µg'), ('Polymyxins', 'Colistin', '10 µg'), ('Oxazolidinones', 'Linezolid', '30 µg'), ] for row_data in antibiotics: row = table.add_row().cells for i, val in enumerate(row_data): row[i].text = val for run in row[i].paragraphs[0].runs: run.font.name = 'Times New Roman' run.font.size = Pt(11) doc.add_paragraph() # ════════════════════════════════════════════════════════════════════════════ # SECTION 7 — SPECIAL RESISTANCE PHENOTYPE DETECTION # ════════════════════════════════════════════════════════════════════════════ add_heading(doc, '3.7 Detection of Special Resistance Phenotypes', level=1) add_para(doc, '3.7.1 Extended-Spectrum Beta-Lactamase (ESBL) Detection', bold=True) add_para(doc, 'Phenotypic screening for ESBL production was performed in Enterobacteriaceae (particularly Escherichia coli and Klebsiella pneumoniae) that showed reduced susceptibility to third-generation cephalosporins (cefotaxime ≤ 27 mm, ceftazidime ≤ 22 mm, or ceftriaxone ≤ 25 mm). The CLSI combined disc method was employed: discs of cefotaxime (30 µg) and ceftazidime (30 µg) alone and in combination with clavulanic acid (10 µg) were placed on Mueller-Hinton agar inoculated with a 0.5 McFarland suspension. An increase of ≥ 5 mm in zone diameter for either cephalosporin in combination with clavulanate compared with the cephalosporin alone confirmed ESBL production.') add_para(doc, '3.7.2 Methicillin-Resistant Staphylococcus aureus (MRSA) Detection', bold=True) add_para(doc, 'MRSA screening was performed using the cefoxitin disc diffusion test. A cefoxitin disc (30 µg) was placed on Mueller-Hinton agar inoculated with a 0.5 McFarland suspension of S. aureus. Plates were incubated at 35°C for 24 hours. A zone diameter of ≤ 21 mm was interpreted as methicillin-resistant (MRSA), and ≥ 22 mm as methicillin-susceptible (MSSA), as per CLSI guidelines.') add_para(doc, '3.7.3 Carbapenem-Resistant Organisms (CRO)', bold=True) add_para(doc, 'Isolates with reduced susceptibility to carbapenems on disc diffusion were flagged as potential carbapenem-resistant organisms (CRO) and reported to the treating clinician. Further confirmatory testing (modified carbapenem inactivation method, mCIM) was performed where feasible, as per institutional protocol.') # ════════════════════════════════════════════════════════════════════════════ # SECTION 8 — DATA COLLECTION AND STATISTICAL ANALYSIS # ════════════════════════════════════════════════════════════════════════════ add_heading(doc, '3.8 Data Collection and Statistical Analysis', level=1) add_para(doc, 'All laboratory and patient data were recorded on a pre-designed, standardised data collection form. Information captured included patient demographics (age, sex, ward/outpatient status), clinical diagnosis, underlying comorbidities (e.g., diabetes mellitus, chronic kidney disease, prior antibiotic use), culture results, species identification, and antibiotic susceptibility profiles. Data were entered into Microsoft Excel 2019 and cross-checked for accuracy before analysis.') add_para(doc, 'Statistical analysis was performed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA) and/or Epi Info version 7. Categorical variables were expressed as frequencies and percentages. Quantitative variables were expressed as means with standard deviations or medians with interquartile ranges as appropriate. Chi-square test or Fisher\'s exact test was applied for comparison of categorical data. A p-value of less than 0.05 was considered statistically significant.') # ════════════════════════════════════════════════════════════════════════════ # SECTION 9 — INCLUSION / EXCLUSION CRITERIA # ════════════════════════════════════════════════════════════════════════════ add_heading(doc, '3.9 Inclusion and Exclusion Criteria', level=1) add_para(doc, 'Inclusion Criteria:', bold=True) inclusion = [ 'All patients aged > 1 year presenting with clinical signs and symptoms of UTI (dysuria, frequency, urgency, haematuria, suprapubic pain, or fever with no other localising source) admitted to or attending the outpatient department of the tertiary care hospital.', 'Urine specimens yielding significant bacterial or fungal growth (≥ 10⁵ CFU/mL) on culture.', 'Patients who provided written informed consent for participation.', ] for item in inclusion: add_bullet(doc, item) add_para(doc, 'Exclusion Criteria:', bold=True) exclusion = [ 'Patients who had received antibiotics within the 48 hours preceding urine sample collection, unless the specimen was taken specifically to investigate treatment failure.', 'Urine specimens that were improperly collected, inadequately labelled, or showed evidence of contamination (squamous epithelial cell count > 10/LPF).', 'Polymicrobial cultures with three or more distinct organisms (considered contaminants).', 'Patients who declined consent or withdrew from the study.', 'Repeat isolates from the same patient (only the first isolate per patient per episode was included to avoid duplication).', ] for item in exclusion: add_bullet(doc, item) # ════════════════════════════════════════════════════════════════════════════ # SECTION 10 — ETHICAL CONSIDERATIONS # ════════════════════════════════════════════════════════════════════════════ add_heading(doc, '3.10 Ethical Considerations', level=1) add_para(doc, 'The study protocol was reviewed and approved by the Institutional Ethics Committee (Ref. No.: ________; Date: ________). The study was conducted in accordance with the ethical principles of the Declaration of Helsinki (revised 2013) and Good Clinical Practice guidelines. Patient identifiers were replaced with unique study codes to ensure confidentiality. Participation was voluntary, and patients were informed of their right to withdraw at any time without any consequence to their clinical care. No additional invasive procedures beyond those required for routine clinical management were performed.') # ════════════════════════════════════════════════════════════════════════════ # SAVE # ════════════════════════════════════════════════════════════════════════════ out_path = '/tmp/workspace/md-thesis-methodology/Methodology_UTI_Bacteriology_Final.docx' doc.save(out_path) print(f'Saved: {out_path}') PYEOF

"urinary tract infection"[MeSH Terms] AND "anti-bacterial agents"[MeSH Terms] AND uropathogens

"urinary tract infection" AND antibiotic resistance India

python3 << 'PYEOF' from docx import Document from docx.shared import Pt, Inches, RGBColor from docx.enum.text import WD_ALIGN_PARAGRAPH doc = Document() # Default style ns = doc.styles['Normal'] ns.font.name = 'Times New Roman' ns.font.size = Pt(12) def heading(doc, text, level=1): h = doc.add_heading(text, level=level) h.alignment = WD_ALIGN_PARAGRAPH.LEFT for run in h.runs: run.font.name = 'Times New Roman' run.bold = True run.font.size = Pt(14) if level == 1 else Pt(13) if level == 2 else Pt(12) return h def para(doc, text, bold=False, italic=False, indent=False, center=False): p = doc.add_paragraph() p.alignment = WD_ALIGN_PARAGRAPH.CENTER if center else WD_ALIGN_PARAGRAPH.JUSTIFY if indent: p.paragraph_format.left_indent = Inches(0.4) r = p.add_run(text) r.font.name = 'Times New Roman' r.font.size = Pt(12) r.bold = bold r.italic = italic return p def bullet(doc, text, indent=0.5): p = doc.add_paragraph(style='List Bullet') p.paragraph_format.left_indent = Inches(indent) r = p.add_run(text) r.font.name = 'Times New Roman' r.font.size = Pt(12) return p def space(doc): p = doc.add_paragraph() p.paragraph_format.space_after = Pt(0) return p # ════════════════════════════════════════════════ # TITLE # ════════════════════════════════════════════════ t = doc.add_paragraph() t.alignment = WD_ALIGN_PARAGRAPH.CENTER r = t.add_run('CHAPTER II: REVIEW OF LITERATURE\nPHARMACOLOGY OF URINARY TRACT INFECTIONS:\nANTIBIOTICS, UROPATHOGENS, AND RESISTANCE MECHANISMS') r.font.name = 'Times New Roman'; r.font.size = Pt(14); r.bold = True doc.add_paragraph() # ════════════════════════════════════════════════ # 1. INTRODUCTION # ════════════════════════════════════════════════ heading(doc, '1. Introduction', 1) para(doc, 'Urinary tract infection (UTI) is one of the most prevalent infectious diseases encountered in both community and hospital settings worldwide. It is defined as the presence of significant bacteriuria (≥10⁵ colony-forming units per millilitre, CFU/mL) with or without accompanying clinical symptoms such as dysuria, increased urinary frequency, urgency, suprapubic discomfort, or fever. UTIs are classified anatomically as lower tract infections (cystitis, urethritis, prostatitis) and upper tract infections (pyelonephritis, perinephric abscess), and clinically as uncomplicated or complicated, depending on the host and structural factors involved.') para(doc, 'In India, UTIs constitute a major public health burden, accounting for a substantial proportion of antibiotic prescriptions in both outpatient and inpatient settings. The epidemiology of uropathogens and their antibiotic susceptibility patterns are shaped by regional factors including antibiotic usage habits, sanitation, healthcare access, and the prevalence of drug-resistant clones. A thorough understanding of the pharmacology of antibiotics used against UTI-causing organisms is therefore essential for rational prescribing, antimicrobial stewardship, and for interpreting susceptibility data generated in surveillance studies such as the present thesis.') # ════════════════════════════════════════════════ # 2. BACTERIOLOGY OF UTI # ════════════════════════════════════════════════ heading(doc, '2. Bacteriological Profile of Uropathogens', 1) para(doc, 'The aetiological spectrum of UTI differs between community-acquired and hospital-acquired (nosocomial) infections, and between uncomplicated and complicated clinical presentations. Table 1 summarises the frequency distribution of uropathogens as described in the literature.') # Table 1 - Bacteriology tbl = doc.add_table(rows=1, cols=4) tbl.style = 'Table Grid' hdr = tbl.rows[0].cells for i, h in enumerate(['Organism', 'Gram Character', 'Uncomplicated UTI', 'Complicated/HAI UTI']): hdr[i].text = h for run in hdr[i].paragraphs[0].runs: run.bold = True; run.font.name = 'Times New Roman'; run.font.size = Pt(11) rows_data = [ ('Escherichia coli', 'Gram-negative rod', '70–80%', '40–50%'), ('Klebsiella pneumoniae', 'Gram-negative rod', '5–10%', '10–15%'), ('Proteus mirabilis', 'Gram-negative rod', '3–5%', '5–7%'), ('Pseudomonas aeruginosa', 'Gram-negative rod', '<1%', '10–15%'), ('Enterobacter spp.', 'Gram-negative rod', '1–2%', '5–8%'), ('Acinetobacter baumannii', 'Gram-negative rod', 'Rare', '5–10%'), ('Staphylococcus saprophyticus', 'Gram-positive coccus', '5–10% (young women)', 'Rare'), ('Staphylococcus aureus (MRSA)', 'Gram-positive coccus', 'Rare', '2–5%'), ('Enterococcus faecalis / faecium', 'Gram-positive coccus', '3–5%', '8–12%'), ('Coagulase-negative Staphylococci (CoNS)', 'Gram-positive coccus', 'Rare', '3–5%'), ('Candida spp.', 'Fungus', 'Rare', '5–10% (catheterised)'), ] for rd in rows_data: row = tbl.add_row().cells for i, v in enumerate(rd): row[i].text = v for run in row[i].paragraphs[0].runs: run.font.name = 'Times New Roman'; run.font.size = Pt(11) space(doc) para(doc, 'Table 1. Frequency distribution of common uropathogens in uncomplicated and complicated UTI.', italic=True) space(doc) # 2.1 Gram-Negative Rods heading(doc, '2.1 Gram-Negative Uropathogens', 2) para(doc, '2.1.1 Escherichia coli', bold=True) para(doc, 'Escherichia coli is responsible for approximately 70–80% of community-acquired UTIs and remains the single most important uropathogen across virtually all patient groups. Uropathogenic E. coli (UPEC) strains are equipped with a range of virulence determinants that facilitate colonisation and invasion of the urinary tract. Type 1 fimbriae (FimH adhesin) mediate attachment to mannosylated uroplakin receptors on urothelial cells, while P-fimbriae (PapG adhesin) bind globoside receptors on renal epithelium, facilitating upper tract ascent. Additional virulence factors include alpha-haemolysin (which lyses erythrocytes and urothelial cells), the iron-acquisition siderophore aerobactin, cytotoxic necrotising factor 1 (CNF1), and the capacity to form intracellular bacterial communities (IBCs) within umbrella cells - a mechanism that enables UPEC to evade both the host immune response and antibiotic concentrations achievable in urine (Flores and Rohn, 2025, PMID 39929975). In Northwestern India, E. coli isolates from UTI demonstrate high rates of fluoroquinolone resistance (often >50%), ESBL production (40–70%), and increasing carbapenem resistance, reflecting the heavy antibiotic selection pressure in this region.') para(doc, 'Key antibiotic choices for E. coli UTI include nitrofurantoin (uncomplicated cystitis), fosfomycin trometamol (single-dose uncomplicated cystitis), cotrimoxazole (when susceptible), fluoroquinolones (where local resistance rates permit), and carbapenems for ESBL-producing strains causing febrile/complicated infection.') para(doc, '2.1.2 Klebsiella pneumoniae', bold=True) para(doc, 'Klebsiella pneumoniae is the second most common uropathogen and is particularly prevalent in hospitalised, diabetic, and immunocompromised patients. Its thick polysaccharide capsule confers resistance to phagocytosis and complement-mediated killing. K. pneumoniae is inherently resistant to ampicillin due to constitutive beta-lactamase production. Of major clinical concern is the high prevalence of ESBL-producing K. pneumoniae (ESBL-Kp) in India, as well as the emergence of carbapenemase-producing strains (OXA-48, NDM-1 types), which severely limit therapeutic options. Treatment for susceptible strains includes third/fourth-generation cephalosporins and fluoroquinolones; for ESBL producers, carbapenems (ertapenem, meropenem) are the drugs of choice; carbapenem-resistant strains require colistin, polymyxin B, ceftazidime-avibactam, or meropenem-vaborbactam.') para(doc, '2.1.3 Proteus mirabilis', bold=True) para(doc, 'Proteus mirabilis produces urease, which hydrolyses urea to ammonia, raising urinary pH and predisposing to struvite (staghorn) calculus formation - a major complication in catheterised patients and those with structural urinary abnormalities. Proteus is motile and capable of swarming on solid media. It is inherently resistant to nitrofurantoin and tetracycline. Ampicillin, cotrimoxazole, and ciprofloxacin are traditional agents; in resistant strains, piperacillin-tazobactam or carbapenems are indicated.') para(doc, '2.1.4 Pseudomonas aeruginosa', bold=True) para(doc, 'Pseudomonas aeruginosa is primarily a nosocomial uropathogen associated with indwelling urinary catheters, urological instrumentation, and intensive care unit (ICU) stays. It is intrinsically resistant to many antibiotics, including most penicillins, first- and second-generation cephalosporins, cotrimoxazole, and nitrofurantoin. Effective anti-pseudomonal agents include ciprofloxacin (with caution due to rising resistance), piperacillin-tazobactam, ceftazidime, cefepime, imipenem, meropenem, and amikacin. Treatment is guided by susceptibility testing. Monotherapy is preferred for uncomplicated infections; combination therapy (e.g., a beta-lactam plus an aminoglycoside) may be used for severe, complicated infections. Multidrug-resistant (MDR) P. aeruginosa requires colistin or ceftolozane-tazobactam.') para(doc, '2.1.5 Enterobacter spp. and Other Enterobacteriaceae', bold=True) para(doc, 'Enterobacter cloacae and Enterobacter aerogenes (now Klebsiella aerogenes) are clinically relevant nosocomial uropathogens. They harbour inducible AmpC beta-lactamases and can develop resistance to third-generation cephalosporins during therapy by derepression of the chromosomal AmpC enzyme. This phenomenon - termed the "inoculum effect" - means that cefotaxime or ceftriaxone should not be used for serious Enterobacter infections even if the in vitro susceptibility test reports susceptibility. Fluoroquinolones, carbapenems, and cefepime (which is a poor AmpC inducer) are appropriate choices.') para(doc, '2.1.6 Acinetobacter baumannii', bold=True) para(doc, 'Acinetobacter baumannii has emerged as a significant nosocomial pathogen, particularly in ICUs and long-term care settings. It is associated with catheter-associated UTI (CAUTI) and post-surgical infections. A. baumannii can acquire a wide range of resistance mechanisms simultaneously, making it a leading MDR organism. Carbapenem-resistant A. baumannii (CRAB) is increasingly common in India. Treatment options for CRAB are severely limited and include colistin (polymyxin E), polymyxin B, sulbactam-containing regimens, tigecycline, and novel combinations such as cefiderocol.') # 2.2 Gram-Positive heading(doc, '2.2 Gram-Positive Uropathogens', 2) para(doc, '2.2.1 Staphylococcus saprophyticus', bold=True) para(doc, 'S. saprophyticus is the second most common cause of uncomplicated lower UTI in sexually active young women (15–35 years), accounting for 5–10% of community-acquired cystitis in this group. It adheres to uroepithelial cells via specific adhesins and produces urease. Unlike S. aureus, it is coagulase-negative and is intrinsically resistant to novobiocin (a useful differentiating feature). It is generally susceptible to nitrofurantoin, ciprofloxacin, trimethoprim, and cotrimoxazole; beta-lactams are also effective.') para(doc, '2.2.2 Enterococcus faecalis and Enterococcus faecium', bold=True) para(doc, 'Enterococci account for 3–12% of UTIs, with higher proportions in hospitalised, elderly, catheterised, and immunocompromised patients. E. faecalis is more common than E. faecium but E. faecium is more difficult to treat due to intrinsic ampicillin resistance and the propensity to acquire vancomycin resistance (VRE). Enterococci are intrinsically resistant to all cephalosporins, clindamycin, cotrimoxazole, and low-level aminoglycosides. Ampicillin (or amoxicillin) is the drug of choice for susceptible E. faecalis; vancomycin is used for ampicillin-resistant strains. For VRE UTI, linezolid, daptomycin, or teicoplanin (VanB phenotype only) are used. Nitrofurantoin retains good activity against E. faecalis and is a useful oral option for uncomplicated cystitis.') para(doc, '2.2.3 Staphylococcus aureus (Including MRSA)', bold=True) para(doc, 'S. aureus as a primary uropathogen is uncommon and usually indicates haematogenous seeding (septicaemia with renal involvement) or a urological procedure. Methicillin-resistant S. aureus (MRSA) in the urinary tract requires vancomycin or teicoplanin (parenteral) or linezolid (oral). For MSSA, anti-staphylococcal penicillins (cloxacillin, nafcillin) or first-generation cephalosporins are preferred. Nitrofurantoin has in vitro activity but is not used for upper tract S. aureus infections.') para(doc, '2.2.4 Coagulase-Negative Staphylococci (CoNS)', bold=True) para(doc, 'CoNS, particularly Staphylococcus epidermidis and Staphylococcus haemolyticus, are important causes of healthcare-associated UTI, particularly in catheterised patients and those who have undergone urological procedures. They are frequent colonisers of urinary catheters via biofilm formation. Treatment is guided by susceptibility testing; many CoNS are methicillin-resistant and require vancomycin or linezolid.') # ════════════════════════════════════════════════ # 3. PHARMACOLOGY OF ANTIBIOTICS # ════════════════════════════════════════════════ heading(doc, '3. Pharmacology of Antibiotics Used in UTI', 1) para(doc, 'The selection of antibiotics for UTI is guided by: (i) the likely causative organism and local resistance patterns; (ii) the clinical syndrome (uncomplicated cystitis vs complicated UTI vs pyelonephritis); (iii) patient factors (age, pregnancy, renal function, allergies); and (iv) the pharmacokinetic/pharmacodynamic (PK/PD) properties of the drug, particularly its urinary excretion, concentration in renal parenchyma, and bactericidal vs bacteriostatic activity. The principal antibiotic classes used are described below.') para(doc, 'The general principle of antibiotic selection is to use the agent with the narrowest effective spectrum, appropriate for the site and clinical severity, guided wherever possible by culture and sensitivity results (Frimodt-Moller and Bjerrum, 2023, PMID 37922147).') # 3.1 Nitrofurantoin heading(doc, '3.1 Nitrofurantoin', 2) para(doc, 'Class: Nitrofuran derivative', bold=True) para(doc, 'Spectrum of Activity:') para(doc, 'Nitrofurantoin has activity against the majority of common uropathogens including E. coli, S. saprophyticus, Enterococcus faecalis, Staphylococcus aureus, Klebsiella spp., and Enterobacter spp. It lacks meaningful activity against Proteus spp. (which produce urease raising urinary pH), Pseudomonas aeruginosa, Acinetobacter spp., Serratia marcescens, and Morganella morganii. It is therefore appropriate only for lower UTI (cystitis) and must never be used for pyelonephritis or febrile upper tract infections.') para(doc, 'Mechanism of Action:') para(doc, 'Nitrofurantoin is a prodrug. Within the bacterial cell, nitroreductase enzymes reduce nitrofurantoin to highly reactive electrophilic intermediates that simultaneously attack multiple bacterial targets: ribosomal proteins (inhibiting protein synthesis), DNA (causing strand breakage), pyruvate metabolism, and the cell wall. This multi-target mechanism explains why bacterial resistance to nitrofurantoin is rare and slow to develop.') para(doc, 'Pharmacokinetics:') para(doc, 'Nitrofurantoin is rapidly absorbed from the gastrointestinal tract and concentrated in the urine, where urinary drug levels far exceed the MIC for susceptible organisms. Serum and tissue concentrations remain sub-therapeutic, explaining why it is confined to the management of lower UTI. The macrocrystalline formulation (Macrobid) slows absorption, reducing gastrointestinal adverse effects. Dose adjustments are required in renal impairment; it is generally contraindicated when creatinine clearance is < 30 mL/min because urinary concentrations become inadequate and the risk of peripheral neuropathy increases.') para(doc, 'Standard Dosing: 50–100 mg orally four times daily for 5–7 days (or 100 mg modified-release twice daily for 5 days).', italic=True) para(doc, 'Adverse Effects:') bullet(doc, 'Gastrointestinal (nausea, vomiting) - most common; reduced by taking with food') bullet(doc, 'Pulmonary reactions (acute hypersensitivity pneumonitis, chronic interstitial pneumonitis with long-term use)') bullet(doc, 'Peripheral neuropathy (with prolonged use or renal impairment)') bullet(doc, 'Haemolytic anaemia in G6PD-deficient patients') bullet(doc, 'Hepatotoxicity (rare, with long-term use)') # 3.2 Cotrimoxazole heading(doc, '3.2 Trimethoprim-Sulfamethoxazole (Cotrimoxazole, TMP-SMX)', 2) para(doc, 'Class: Folate synthesis inhibitor (combination of a diaminopyrimidine + sulfonamide)', bold=True) para(doc, 'Spectrum of Activity:') para(doc, 'Cotrimoxazole is active against E. coli, Klebsiella spp., Proteus mirabilis, and many other Enterobacteriaceae. It does not cover Enterococcus or Pseudomonas. In India and other parts of South Asia, resistance of E. coli to TMP-SMX has risen substantially (often >50%), limiting its empiric use. In vitro susceptibility testing is essential before prescribing.') para(doc, 'Mechanism of Action:') para(doc, 'Trimethoprim inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, which is essential for thymidine, purines, and certain amino acid synthesis. Sulfamethoxazole, a structural analogue of para-aminobenzoic acid (PABA), competitively inhibits dihydropteroate synthase, blocking an earlier step in the folate synthesis pathway. The two drugs act sequentially at different points in the same pathway, producing synergistic bactericidal activity. Human DHFR has 100,000 times lower affinity for trimethoprim than bacterial DHFR, providing selective toxicity.') para(doc, 'Standard Dosing: 960 mg (800/160 mg) orally twice daily for 3–5 days (cystitis) or 10–14 days (pyelonephritis).', italic=True) para(doc, 'Adverse Effects: Hypersensitivity (including Stevens-Johnson syndrome), marrow suppression, haemolytic anaemia (G6PD deficiency), hyperkalaemia (trimethoprim inhibits renal potassium excretion), nephrotoxicity. Avoid in the third trimester of pregnancy (risk of neonatal jaundice).') # 3.3 Fluoroquinolones heading(doc, '3.3 Fluoroquinolones (Ciprofloxacin, Norfloxacin, Levofloxacin, Ofloxacin)', 2) para(doc, 'Class: Fluorinated 4-quinolone antibiotics', bold=True) para(doc, 'Spectrum of Activity:') para(doc, 'Fluoroquinolones have broad-spectrum activity covering most Gram-negative uropathogens, including E. coli, Klebsiella spp., Proteus spp., Pseudomonas aeruginosa (ciprofloxacin/levofloxacin), Enterobacter spp., and Serratia spp. Activity against Gram-positive cocci (S. aureus, Enterococcus) is variable and generally inferior. They are active against intracellular organisms (Chlamydia trachomatis, Mycoplasma). Norfloxacin achieves high urinary but poor systemic concentrations and is therefore suitable only for uncomplicated lower UTI. Ciprofloxacin and levofloxacin achieve good tissue and systemic concentrations and are used for both lower and upper UTI.') para(doc, 'Mechanism of Action:') para(doc, 'Fluoroquinolones inhibit two essential bacterial type II topoisomerases: DNA gyrase (topoisomerase II) and topoisomerase IV. DNA gyrase introduces negative supercoils into DNA, facilitating replication and transcription; topoisomerase IV separates interlinked daughter chromosomes after replication. Fluoroquinolone binding stabilises the enzyme-DNA cleavage complex, blocking DNA replication and repair, leading to rapid bactericidal activity. In Gram-negative bacteria, the primary target is DNA gyrase (GyrA subunit); in Gram-positive bacteria, it is topoisomerase IV (ParC subunit).') para(doc, 'Resistance Mechanisms:') bullet(doc, 'Target mutations: Point mutations in gyrA and parC genes that reduce drug binding') bullet(doc, 'Efflux pumps: Overexpression of chromosomally encoded efflux pumps (MexAB-OprM in P. aeruginosa; AcrAB-TolC in Enterobacteriaceae) that actively expel fluoroquinolones') bullet(doc, 'Plasmid-mediated quinolone resistance (PMQR): qnr genes encode pentapeptide repeat proteins that protect topoisomerases; aac(6\')Ib-cr acetylates ciprofloxacin; oqxAB and qepA encode plasmid-mediated efflux pumps') bullet(doc, 'Outer membrane porin loss: Reduced drug uptake in Gram-negative organisms') para(doc, 'Standard Dosing (UTI):') bullet(doc, 'Ciprofloxacin: 250–500 mg orally twice daily (cystitis 3 days; pyelonephritis 7–14 days)') bullet(doc, 'Levofloxacin: 250–500 mg orally once daily (uncomplicated cystitis 3 days; pyelonephritis 5–10 days)') bullet(doc, 'Norfloxacin: 400 mg orally twice daily (lower UTI only, 3–7 days)') para(doc, 'Adverse Effects: Tendinopathy and tendon rupture (especially Achilles tendon in elderly and steroid users), QT interval prolongation, CNS effects (dizziness, insomnia, rarely seizures), photosensitivity, peripheral neuropathy, hypoglycaemia in diabetics on sulfonylureas, cartilage toxicity (contraindicated in children and pregnancy).') # 3.4 Cephalosporins heading(doc, '3.4 Cephalosporins', 2) para(doc, 'Class: Beta-lactam antibiotics (cephem nucleus)', bold=True) para(doc, 'Spectrum of Activity by Generation:') bullet(doc, '1st generation (cefalexin, cefazolin): Active against Gram-positive cocci (S. aureus MSSA, streptococci), E. coli, Klebsiella, Proteus mirabilis. Limited anaerobic activity.') bullet(doc, '2nd generation (cefuroxime, cefaclor): Broader Gram-negative coverage including Haemophilus influenzae; retained Gram-positive activity.') bullet(doc, '3rd generation (cefotaxime, ceftriaxone, ceftazidime, cefixime): Excellent Gram-negative Enterobacteriaceae coverage. Ceftazidime also active against Pseudomonas. Reduced Gram-positive activity compared to 1st generation. Oral cefixime is widely used for uncomplicated cystitis and as step-down therapy in pyelonephritis.') bullet(doc, '4th generation (cefepime): Extended coverage including Pseudomonas and AmpC-producing organisms; retains Gram-positive activity.') bullet(doc, '5th generation (ceftaroline, ceftobiprole): Active against MRSA; not commonly used for UTI.') para(doc, 'Mechanism of Action:') para(doc, 'Cephalosporins, like all beta-lactams, bind irreversibly to penicillin-binding proteins (PBPs) - the enzymes (DD-transpeptidases) responsible for the final cross-linking step in peptidoglycan biosynthesis. Inhibition of PBPs prevents cell wall synthesis, resulting in osmotic lysis of actively growing bacteria. Bactericidal activity is time-dependent (efficacy correlates with the time free drug concentration remains above the MIC, %T>MIC).') para(doc, 'Resistance:') para(doc, 'The principal resistance mechanism is beta-lactamase production. Extended-spectrum beta-lactamases (ESBLs) - predominantly TEM, SHV, and CTX-M types - hydrolyse 3rd-generation cephalosporins and are common in E. coli and K. pneumoniae in India. AmpC beta-lactamases (chromosomal or plasmid-mediated) confer resistance to 1st through 3rd generation cephalosporins and are not inhibited by clavulanate. Carbapenemases (KPC, NDM, OXA-48) confer resistance to carbapenems.') para(doc, 'Note on ESBLs in India:', bold=True) para(doc, 'ESBLs are classified as enzymes capable of hydrolysing oxyimino-cephalosporins (ceftazidime, ceftriaxone, cefotaxime) and monobactams but which are inhibited by clavulanic acid in vitro. The prevalence of ESBL-producing E. coli and Klebsiella in UTI isolates from tertiary care hospitals in Northwestern India has been reported in the range of 40–70%. The phenotypic criterion for ESBL detection (CLSI combined disc test: ≥5 mm increase in zone diameter with cephalosporin + clavulanate vs cephalosporin alone) is the standard method used in routine practice.') # 3.5 Aminoglycosides heading(doc, '3.5 Aminoglycosides (Gentamicin, Amikacin, Tobramycin, Netilmicin)', 2) para(doc, 'Class: Aminocyclitol-aminoglycoside antibiotics', bold=True) para(doc, 'Spectrum of Activity:') para(doc, 'Aminoglycosides are highly active against aerobic Gram-negative bacilli, including E. coli, Klebsiella, Proteus, Pseudomonas aeruginosa, Acinetobacter, Serratia, and Enterobacter. Gentamicin combined with a cell-wall active agent (ampicillin or vancomycin) is synergistically bactericidal against Enterococcus and Streptococcus viridans group. They have no useful anaerobic or Gram-positive (except synergy) activity on their own.') para(doc, 'Mechanism of Action:') para(doc, 'Aminoglycosides enter the bacterial cell in an energy-dependent process (facilitated by the proton motive force) and bind irreversibly to the 30S ribosomal subunit (primarily the 16S rRNA component, helix 44, at the decoding A-site). This binding causes misreading of the mRNA codon, leading to insertion of incorrect amino acids into the growing polypeptide chain. The resulting aberrant proteins are inserted into the cell membrane, creating ionic channels that further increase drug uptake (self-promoted uptake), amplifying the bactericidal effect. Bactericidal activity is concentration-dependent (efficacy correlates with the peak serum concentration to MIC ratio, Cmax/MIC).') para(doc, 'Clinical Role in UTI:') para(doc, 'Gentamicin is a first-line parenteral agent for complicated UTI and acute pyelonephritis when the patient requires intravenous therapy, particularly in settings with high fluoroquinolone resistance. Amikacin is reserved for gentamicin-resistant or multidrug-resistant organisms because it is protected from most aminoglycoside-modifying enzymes (AMEs) by its hydroxylaminobutyryl side chain. Single daily dosing (once-daily gentamicin, e.g., 5 mg/kg IV daily in normal renal function) achieves higher peak/MIC ratios and is preferred to multiple-daily dosing for efficacy while reducing nephrotoxicity.') para(doc, 'Adverse Effects: Nephrotoxicity (proximal tubular damage, reversible), ototoxicity (cochlear and vestibular, often irreversible), neuromuscular blockade (rare). Therapeutic drug monitoring (TDM) is mandatory, with trough levels (<1 mg/L for once-daily regimens) guiding dosing. Dose reductions are essential in renal impairment.') # 3.6 Beta-Lactam + BLI Combinations heading(doc, '3.6 Beta-Lactam / Beta-Lactamase Inhibitor (BL/BLI) Combinations', 2) para(doc, 'Key agents: Amoxicillin-clavulanate, Ampicillin-sulbactam, Piperacillin-tazobactam, Ceftolozane-tazobactam, Ceftazidime-avibactam', bold=True) para(doc, 'Mechanism:') para(doc, 'Beta-lactamase inhibitors (clavulanic acid, sulbactam, tazobactam) act as "suicide inhibitors" - they bind irreversibly to the active site serine of class A beta-lactamases (ESBLs, TEM, SHV, CTX-M), protecting the partner beta-lactam from hydrolysis. However, they do not significantly inhibit class C AmpC beta-lactamases or class B metallo-beta-lactamases (NDM, VIM, IMP). Avibactam is a non-beta-lactam BLI that inhibits class A, C, and some class D enzymes, broadening coverage to ESBL- and KPC-producers (but not NDM).') para(doc, 'Clinical Role:') bullet(doc, 'Amoxicillin-clavulanate: Oral agent for uncomplicated UTI caused by ESBL-negative E. coli or Klebsiella when TMP-SMX resistance is confirmed. Also used in Proteus and Enterococcus.') bullet(doc, 'Piperacillin-tazobactam: IV agent for complicated UTI and pyelonephritis with anti-pseudomonal activity; used for ESBL-producers (with caution - inoculum effect concerns).') bullet(doc, 'Ceftazidime-avibactam: Reserved for KPC-producing carbapenem-resistant Enterobacteriaceae (CRE).') # 3.7 Carbapenems heading(doc, '3.7 Carbapenems (Imipenem-Cilastatin, Meropenem, Ertapenem, Doripenem)', 2) para(doc, 'Class: Carbapenem beta-lactams', bold=True) para(doc, 'Spectrum of Activity:') para(doc, 'Carbapenems have the broadest antibacterial spectrum of any beta-lactam class. They are active against ESBL-producing Enterobacteriaceae, AmpC-producing organisms, Pseudomonas aeruginosa (imipenem, meropenem, doripenem - NOT ertapenem), Acinetobacter, MRSA (not fully), Enterococcus (partial), and most anaerobes. They are the definitive treatment for infections caused by ESBL-producing E. coli and Klebsiella. Ertapenem lacks anti-pseudomonal and anti-Acinetobacter activity but is highly effective against Enterobacteriaceae and can be given as once-daily IV or IM injection.') para(doc, 'Mechanism of Action:') para(doc, 'Like all beta-lactams, carbapenems inhibit PBPs. They have a unique structural feature (a 1-beta-methyl group in meropenem) that confers stability to both chromosomal AmpC and plasmid-mediated ESBLs. They are poor substrates for most beta-lactamases. Their rapid, concentration-independent bactericidal activity (time-dependent, T>MIC) and excellent tissue penetration make them appropriate for severe or complicated infections.') para(doc, 'Clinical Role in UTI:') para(doc, 'Carbapenems are second-line (reserved) agents and should not be used empirically when alternative agents are likely to be effective, to preserve their activity. They are indicated for: (i) complicated UTI/pyelonephritis caused by confirmed ESBL-producing E. coli or Klebsiella; (ii) UTI caused by organisms with class C (AmpC) resistance patterns; (iii) severe urosepsis requiring broad-spectrum cover pending culture results. Carbapenem-resistant organisms (CRO) producing metallo-beta-lactamases (NDM-1, most prevalent in India) are not inhibited by any currently available carbapenem-BLI combination (including ceftazidime-avibactam); colistin-based combinations are required.') # 3.8 Fosfomycin heading(doc, '3.8 Fosfomycin Trometamol', 2) para(doc, 'Class: Phosphonic acid antibiotic', bold=True) para(doc, 'Fosfomycin trometamol is available as a single oral dose (3 g sachet) for uncomplicated lower UTI in women. Its mechanism involves inhibition of MurA (UDP-N-acetylglucosamine enolpyruvyl transferase), the first committed step in bacterial peptidoglycan biosynthesis. It achieves very high urinary concentrations after a single dose and has activity against E. coli, E. faecalis, K. pneumoniae, and many ESBL-producing organisms. It has no meaningful activity against Pseudomonas. High patient adherence (single-dose regimen), retained efficacy against ESBL-E. coli, and a low rate of collateral ecological damage make fosfomycin a preferred agent in antimicrobial stewardship frameworks for uncomplicated cystitis. It is not suitable for upper tract infections.') # 3.9 Vancomycin / Glycopeptides heading(doc, '3.9 Glycopeptides (Vancomycin, Teicoplanin)', 2) para(doc, 'Class: Glycopeptide antibiotics', bold=True) para(doc, 'Glycopeptides are active exclusively against Gram-positive organisms. They inhibit cell wall synthesis by binding to the D-Ala-D-Ala terminus of the peptidoglycan precursor lipid II, preventing transpeptidation and transglycosylation. In the context of UTI, vancomycin is used for: (i) MRSA UTI; (ii) VRE infection (vancomycin-resistant enterococci - VanB phenotype only, as VanA is resistant to both vancomycin and teicoplanin); (iii) coagulase-negative staphylococci resistant to beta-lactams. Vancomycin must be administered intravenously; it is not absorbed orally and does not achieve adequate urinary concentrations after oral administration. Therapeutic drug monitoring (trough levels 10–20 mg/L for serious infections; AUC/MIC-guided dosing is now preferred) is mandatory.') # 3.10 Linezolid heading(doc, '3.10 Linezolid', 2) para(doc, 'Class: Oxazolidinone', bold=True) para(doc, 'Linezolid inhibits bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit, preventing the formation of the 70S initiation complex. It is active against MRSA, VRE, and multi-resistant Gram-positive organisms. It is available in both oral (100% bioavailability) and intravenous formulations. In UTI, it is used for VRE cystitis, MRSA urinary infections, and as an alternative in patients who cannot tolerate vancomycin. Adverse effects include myelosuppression (thrombocytopenia with courses > 2 weeks), serotonin syndrome (monoamine oxidase inhibitor activity - avoid with SSRIs/SNRIs), peripheral and optic neuropathy with prolonged use.') # 3.11 Colistin / Polymyxins heading(doc, '3.11 Colistin (Polymyxin E) and Polymyxin B', 2) para(doc, 'Class: Polypeptide antibiotics (polymyxins)', bold=True) para(doc, 'Colistin and polymyxin B are last-resort agents for infections caused by MDR/XDR (extensively drug-resistant) Gram-negative organisms. Their mechanism involves electrostatic disruption of the lipopolysaccharide (LPS) component of the outer membrane of Gram-negative bacteria, leading to membrane permeabilisation and bacterial death. They are active against carbapenem-resistant Pseudomonas aeruginosa, Acinetobacter baumannii, and most carbapenem-resistant Enterobacteriaceae (CRE). Intrinsically resistant organisms include Gram-positive bacteria, Burkholderia, Serratia, Proteus, and Providencia. Nephrotoxicity (dose-dependent tubular injury) and neurotoxicity (peripheral neuropathy, neuromuscular blockade) are major adverse effects. Colistin is increasingly used in combination (colistin + carbapenem, or colistin + rifampicin) for synergistic bactericidal activity in XDR infections.') # ════════════════════════════════════════════════ # 4. ANTIBIOTIC THERAPY BY UTI SYNDROME # ════════════════════════════════════════════════ heading(doc, '4. Antibiotic Therapy by Clinical Syndrome', 1) heading(doc, '4.1 Uncomplicated Cystitis (Non-Pregnant Women)', 2) para(doc, 'Uncomplicated cystitis is defined as lower UTI in a healthy, non-pregnant woman without structural or functional urinary tract abnormality. The dominant organism is E. coli (70–85%), followed by S. saprophyticus (5–15%) and K. pneumoniae.') para(doc, 'First-line agents (IDSA/EAU guidelines, adapted for Indian resistance context):') bullet(doc, 'Nitrofurantoin monohydrate/macrocrystals: 100 mg twice daily x 5 days (preferred; low resistance, ecological safety)') bullet(doc, 'Fosfomycin trometamol: 3 g single oral dose (convenient; effective against ESBL-producers)') bullet(doc, 'Cotrimoxazole (TMP-SMX): 960 mg twice daily x 3 days (only if local E. coli resistance <20%)') para(doc, 'Alternative agents (when first-line are unsuitable):') bullet(doc, 'Fluoroquinolones (ciprofloxacin 250 mg BD x 3 days, or norfloxacin 400 mg BD x 3 days) - avoid as first-line to preserve activity for complicated infections') bullet(doc, 'Oral cephalosporins (cefixime, cefalexin) - less effective than fluoroquinolones; 3–7 days') bullet(doc, 'Amoxicillin-clavulanate - useful when beta-lactamase negative organisms confirmed') heading(doc, '4.2 Acute Uncomplicated Pyelonephritis', 2) para(doc, 'Pyelonephritis requires agents that achieve adequate parenchymal tissue concentrations, not just urinary concentrations. Mild-to-moderate disease can be managed with oral therapy in an outpatient setting; severe disease requires hospital admission and parenteral antibiotics.') para(doc, 'Oral outpatient regimens (mild-moderate):') bullet(doc, 'Ciprofloxacin: 500 mg twice daily x 7 days (if fluoroquinolone susceptibility confirmed)') bullet(doc, 'Levofloxacin: 750 mg once daily x 5 days') bullet(doc, 'Cotrimoxazole: 960 mg twice daily x 14 days (only if susceptible)') bullet(doc, 'Oral third-generation cephalosporin (cefixime): 400 mg daily x 10–14 days') para(doc, 'Parenteral regimens (severe/hospitalised):') bullet(doc, 'Ceftriaxone: 1–2 g IV once daily (initial empiric choice where ESBL prevalence is not overwhelming)') bullet(doc, 'Ciprofloxacin IV / Levofloxacin IV: when Gram-negative infection confirmed') bullet(doc, 'Gentamicin: 5–7 mg/kg IV once daily (where fluoroquinolone resistance is high)') bullet(doc, 'Piperacillin-tazobactam: 4.5 g IV every 6–8 hours (suspected Pseudomonas; polymicrobial)') bullet(doc, 'Meropenem / Imipenem / Ertapenem: for ESBL-producing organisms or severe sepsis') para(doc, 'Note: Nitrofurantoin is CONTRAINDICATED for pyelonephritis - it does not achieve adequate renal parenchymal drug concentrations.', italic=True) heading(doc, '4.3 Complicated UTI (Including CAUTI)', 2) para(doc, 'Complicated UTI encompasses infection in patients with structural abnormalities, indwelling catheters, urological procedures, renal impairment, diabetes, immunosuppression, pregnancy, or male sex. The bacteriological spectrum is broader, with a higher frequency of Klebsiella, Pseudomonas, Enterococcus, Acinetobacter, and drug-resistant strains. Treatment should be guided by culture and susceptibility results wherever possible. Duration is typically 7–14 days. CAUTI management includes removal or replacement of the catheter where clinically feasible.') heading(doc, '4.4 Hospital-Acquired / Nosocomial UTI', 2) para(doc, 'Nosocomial UTI, particularly CAUTI, commonly involves MDR organisms. Empiric therapy must be guided by the institution\'s antibiogram. In settings with high ESBL prevalence, carbapenems are often required empirically for severe presentations. For MDR Pseudomonas or CRAB, colistin-based combination regimens are used. The importance of strict catheter care, hand hygiene, and early catheter removal cannot be overstated in the prevention of CAUTI.') # ════════════════════════════════════════════════ # 5. RESISTANCE MECHANISMS # ════════════════════════════════════════════════ heading(doc, '5. Mechanisms of Antibiotic Resistance in Uropathogens', 1) para(doc, 'The emergence and spread of antibiotic resistance among uropathogens has become a major global health challenge. In India, several interconnected factors - high antibiotic use, over-the-counter availability, agricultural antibiotic use, inadequate sanitation, and healthcare infrastructure gaps - have created a landscape of unusually high resistance rates (Alam et al., 2024, PMID 39297593). The principal resistance mechanisms are:') heading(doc, '5.1 Enzymatic Inactivation', 2) bullet(doc, 'Beta-lactamases (TEM, SHV, CTX-M ESBLs): Hydrolysis of beta-lactam ring in penicillins and cephalosporins') bullet(doc, 'AmpC cephalosporinases: Chromosomal (E. cloacae, P. aeruginosa, Citrobacter) or plasmid-mediated; hydrolyse 1st-3rd generation cephalosporins; not inhibited by clavulanate') bullet(doc, 'Carbapenemases: Class A (KPC), Class B metallo-beta-lactamases (NDM-1, VIM, IMP), Class D (OXA-48); hydrolyse carbapenems') bullet(doc, 'Aminoglycoside-modifying enzymes (AMEs): acetyltransferases, nucleotidyltransferases, phosphotransferases modify the aminoglycoside molecule preventing ribosomal binding') heading(doc, '5.2 Target Modification', 2) bullet(doc, 'PBP mutations (MRSA: mecA-encoded PBP2a with low beta-lactam affinity; VRSA: vanA)') bullet(doc, 'DNA gyrase/topoisomerase IV mutations (fluoroquinolone resistance)') bullet(doc, 'Ribosomal methylation: erm genes methylate 23S rRNA, conferring macrolide-lincosamide-streptogramin B (MLS-B) resistance') bullet(doc, 'Van genes (VRE): vanA, vanB alter D-Ala-D-Ala to D-Ala-D-Lac (vanA/vanB) or D-Ala-D-Ser (vanC), reducing glycopeptide binding affinity by 1000-fold') heading(doc, '5.3 Efflux Pumps', 2) bullet(doc, 'RND family pumps (AcrAB-TolC in E. coli; MexAB-OprM in P. aeruginosa) efflux multiple antibiotic classes simultaneously - a major mechanism of multidrug resistance (MDR)') bullet(doc, 'MATE and MFS family pumps: Additional efflux systems with narrower substrate specificities') heading(doc, '5.4 Permeability Reduction', 2) bullet(doc, 'Loss of outer membrane porins (OmpF, OmpC in Enterobacteriaceae; OprD in P. aeruginosa) reduces intracellular drug accumulation - particularly important for carbapenems in P. aeruginosa (OprD loss + efflux pump upregulation)') heading(doc, '5.5 Biofilm Formation', 2) bullet(doc, 'Biofilm-associated organisms (Pseudomonas, CoNS, E. coli, Enterococcus) are protected from antibiotics by the extracellular polymeric substance (EPS) matrix, which impedes drug diffusion; reduced metabolic activity within the biofilm renders bactericidal agents less effective; persister cells within biofilms can survive prolonged antibiotic exposure and seed recurrent infection after treatment cessation') # ════════════════════════════════════════════════ # 6. ANTIBIOTIC-ORGANISM CORRELATION TABLE # ════════════════════════════════════════════════ heading(doc, '6. Summary: Antibiotic-Organism Correlation Table for UTI', 1) para(doc, 'Table 2 summarises the recommended antibiotic options for each major uropathogen encountered in clinical practice, combining textbook guidance with current resistance considerations for Northwestern India.') space(doc) tbl2 = doc.add_table(rows=1, cols=4) tbl2.style = 'Table Grid' hdr2 = tbl2.rows[0].cells for i, h in enumerate(['Uropathogen', 'First-Line Oral', 'First-Line Parenteral', 'Notes / Resistance Concerns']): hdr2[i].text = h for run in hdr2[i].paragraphs[0].runs: run.bold = True; run.font.name = 'Times New Roman'; run.font.size = Pt(10) org_data = [ ('E. coli (susceptible)', 'Nitrofurantoin; Fosfomycin; TMP-SMX (if susceptible)', 'Gentamicin; Ceftriaxone', 'Most common uropathogen; confirm susceptibility'), ('E. coli (ESBL-producing)', 'Fosfomycin; Nitrofurantoin (cystitis only)', 'Meropenem / Ertapenem; Amikacin', 'Cephalosporins contraindicated; avoid BL/BLI for severe disease'), ('Klebsiella pneumoniae (susceptible)', 'TMP-SMX; Ciprofloxacin; Cefixime', 'Gentamicin; Ceftriaxone', 'Intrinsically ampicillin-resistant'), ('Klebsiella pneumoniae (ESBL)', 'Fosfomycin; Nitrofurantoin (cystitis)', 'Ertapenem / Meropenem', 'ESBL highly prevalent in India; carbapenem needed'), ('CRE (KPC/NDM)', 'Fosfomycin (if susceptible)', 'Colistin ± Meropenem; Ceftazidime-avibactam (KPC only)', 'NDM not inhibited by avibactam; treatment options very limited'), ('Proteus mirabilis', 'TMP-SMX; Ciprofloxacin; Amoxicillin (if susceptible)', 'Ceftriaxone; Piperacillin-tazobactam', 'Intrinsically resistant to nitrofurantoin and tetracycline'), ('Pseudomonas aeruginosa', 'Ciprofloxacin (if susceptible)', 'Piperacillin-tazobactam; Ceftazidime; Meropenem; Amikacin', 'MDR common; colistin for XDR strains'), ('Acinetobacter baumannii (MDR)', 'None reliable', 'Colistin ± Carbapenem; Sulbactam-based; Tigecycline', 'CRAB increasing in India; treatment very challenging'), ('Enterococcus faecalis', 'Amoxicillin; Nitrofurantoin (cystitis)', 'Ampicillin ± Gentamicin (synergy)', 'Inherently resistant to cephalosporins and TMP-SMX'), ('Enterococcus faecium (VRE)', 'Linezolid', 'Linezolid; Daptomycin', 'VanA: resistant to both vancomycin and teicoplanin'), ('S. saprophyticus', 'Nitrofurantoin; TMP-SMX; Ciprofloxacin', 'Ampicillin', 'Young women; cystitis; inherently novobiocin-resistant'), ('MRSA (urinary)', 'Linezolid', 'Vancomycin; Teicoplanin', 'cefoxitin disc confirms MRSA; confirm vancomycin MIC'), ('CoNS (MRSE)', 'Linezolid (oral)', 'Vancomycin; Daptomycin', 'Common in CAUTI; biofilm formers'), ('Candida spp. (CAUTI)', 'Fluconazole (C. albicans)', 'Micafungin; Anidulafungin; Amphotericin B (resistant)', 'Remove/change catheter first; fluconazole-resistant C. krusei/glabrata'), ] for rd in org_data: row = tbl2.add_row().cells for i, v in enumerate(rd): row[i].text = v for run in row[i].paragraphs[0].runs: run.font.name = 'Times New Roman'; run.font.size = Pt(10) space(doc) para(doc, 'Table 2. Antibiotic-uropathogen correlation for UTI management. Abbreviations: ESBL, extended-spectrum beta-lactamase; CRE, carbapenem-resistant Enterobacteriaceae; MRSA, methicillin-resistant S. aureus; VRE, vancomycin-resistant enterococci; CRAB, carbapenem-resistant Acinetobacter baumannii; CAUTI, catheter-associated UTI; MDR, multidrug-resistant; XDR, extensively drug-resistant; BL/BLI, beta-lactam/beta-lactamase inhibitor.', italic=True) # ════════════════════════════════════════════════ # 7. RELEVANCE TO THESIS # ════════════════════════════════════════════════ heading(doc, '7. Relevance to the Present Study', 1) para(doc, 'The present cross-sectional study, conducted at a tertiary care hospital in Northwestern India, aims to document the contemporary bacteriological profile of UTI and the antibiotic susceptibility pattern of isolated uropathogens using the Kirby-Bauer disc diffusion method interpreted according to CLSI guidelines. The pharmacological background detailed in this chapter underpins the clinical relevance of the study\'s findings in the following ways:') bullet(doc, 'Identifying the frequency of ESBL-producing E. coli and Klebsiella informs the empiric use of carbapenems vs cephalosporins in the study institution.') bullet(doc, 'Documenting fluoroquinolone resistance rates guides whether ciprofloxacin or norfloxacin remains a reliable empiric choice for outpatient UTI in this region.') bullet(doc, 'Characterising the susceptibility profiles of non-fermenting Gram-negative bacilli (Pseudomonas, Acinetobacter) identifies the proportion of patients who may require colistin or other last-resort agents.') bullet(doc, 'Enterococcal susceptibility data (particularly VRE prevalence) determine the clinical utility of nitrofurantoin, linezolid, and vancomycin in this setting.') bullet(doc, 'The antibiogram generated from this study will serve as an evidence base for formulating institution-specific empiric antibiotic prescribing guidelines, contributing to antimicrobial stewardship.') para(doc, 'The data from this study will be interpreted in the context of national and international surveillance data (ICMR-GLASS reports, ESKAPE pathogen surveillance networks), providing a regionally specific contribution to the growing body of literature on antibiotic resistance among uropathogens in India.') # ════════════════════════════════════════════════ # REFERENCES # ════════════════════════════════════════════════ heading(doc, '8. Key References', 1) refs = [ 'Smith and Tanagho\'s General Urology, 19th Edition. Chapter 14: Urinary Tract Infections and Antibiotic Use.', 'Tintinalli\'s Emergency Medicine: A Comprehensive Study Guide, 9th Edition. Chapter 91: Urinary Tract Infections and Hematuria.', "Rosen's Emergency Medicine: Concepts and Clinical Practice, 9th Edition. Chapter on Urinary Tract Infection.", 'Campbell-Walsh-Wein Urology, 12th Edition. Chapter on Urinary Tract Infections.', 'Frimodt-Moller N, Bjerrum L. Treating urinary tract infections in the era of antibiotic resistance. Expert Rev Anti Infect Ther. 2023;21(12):1367-1374. PMID: 37922147.', 'Alam MS, Anwar MJ, Akhtar MS. A systematic review of recent advances in urinary tract infection interventions and treatment technology. Eur Rev Med Pharmacol Sci. 2024. PMID: 39297593.', 'Flores C, Rohn JL. Bacterial adhesion strategies and countermeasures in urinary tract infection. Nat Microbiol. 2025. PMID: 39929975.', 'Wagenlehner FME. New antibiotics for the treatment of urinary tract infections. Urologe. 2023;62(7):699-705. PMID: 37306723.', 'Guerriero S, Matteini E, Gross MM. Complicated urinary tract infections: an update of new and developing antibiotics. Expert Opin Pharmacother. 2025. PMID: 39773267.', 'CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 33rd ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, 2023.', 'ICMR Annual Report on Antimicrobial Resistance. New Delhi: Indian Council of Medical Research (latest edition at time of study).', ] for i, r in enumerate(refs, 1): p = doc.add_paragraph() p.paragraph_format.left_indent = Inches(0.4) p.paragraph_format.first_line_indent = Inches(-0.4) run = p.add_run(f'{i}. {r}') run.font.name = 'Times New Roman' run.font.size = Pt(11) out_path = '/tmp/workspace/md-thesis-methodology/Pharmacology_UTI_Antibiotics_Thesis.docx' doc.save(out_path) print(f'Saved: {out_path}') PYEOF